When Spark Therapeutics announced an $850,000 price for its gene therapy Luxturna last week, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the
read moreLawyers for a former Insys executive implicated in an alleged kickback scheme figure jurors may have strong feelings about the use of highly addictive painkillers. They are asking that prosecutors not be allowed to use the term “opioid crisis” during
read moreBristol-Myers Squibb’s Opdivo is currently the only immuno-oncology treatment approved to treat kidney cancer—but yet another pair of rivals is now moving in to threaten that status. More: Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field Source:
read moreTakeda, which just reached a neurodegenerative deal with Denali, is buying up TiGenix; Opdivo and Lynparza are among 16 potential blockbuster nods in China this year; several Indian and Chinese firms are reportedly eyeing Sanofi’s European generics unit; plus more
read moreUK supermarket giant Tesco will share anonymised sales information with partner charities in a bid to help develop insight on health policy and public health programmes. More: Tesco teams up with UK charities to boost public health Source: News
read moreThe NHS has now chosen 138 clinical entrepreneurs to design and deliver new technological solutions and innovations in healthcare, including the appointment of five healthcare scientists working on addressing conditions such as sickle cell disease and allergic reactions. More: NHS
read more© 1994 - 2026 B.M. Pharmaceuticals